Compare BSRR & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSRR | CATX |
|---|---|---|
| Founded | 1977 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.7M | 497.9M |
| IPO Year | 2001 | 2018 |
| Metric | BSRR | CATX |
|---|---|---|
| Price | $38.10 | $3.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $37.00 | $12.11 |
| AVG Volume (30 Days) | 46.6K | ★ 1.3M |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | ★ 10.28 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.74 | N/A |
| Revenue Next Year | $3.63 | N/A |
| P/E Ratio | $39.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.49 | $1.96 |
| 52 Week High | $38.87 | $6.16 |
| Indicator | BSRR | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 59.54 | 49.91 |
| Support Level | $36.00 | $3.93 |
| Resistance Level | $38.45 | $4.20 |
| Average True Range (ATR) | 0.89 | 0.27 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 75.53 | 66.91 |
Sierra Bancorp is a California-based bank holding company, which offers a range of retail and commercial banking services. it offers a wide range of deposit products and services for individuals and businesses including checking accounts, savings accounts, money market demand accounts, time deposits, retirement accounts, and sweep accounts. The company's lending activities cover real estate, commercial (including small business), mortgage warehouse, agricultural and consumer loans, and also offers commercial construction loans and multifamily and agricultural credit facilities among other types of real estate loans.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.